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Background/aim: CoronaVac is an inactivated virus-based COVID-19 vaccine used in Turkey and approved for emergency use by the
World Health Organization (WHO). In this study, it was aimed to retrospectively evaluate the mutation status and clinical status in
individuals who received two doses of CoronaVac vaccine and were infected with COVID-19 at least two weeks after the second dose.
Materials and methods: 164 people were included in the study and COVID-19 diagnosis and mutation analyses were determined by
RT-PCR using the Bioseepdy SARS CoV-2 Double Gene RT-qPCR Kit and the Biospeedy SARS-CoV-2 Variant Plus kit in accordance
with the protocol determined by the manufacturer.
Results: 116 (70.7%) UK (Alpha, B.1.1.7) mutation and 3 (1.8%) South Africa (Beta, B.1.351), Brazil (Gamma, P.1) mutations were
determined in 164 double doses CoronaVac vaccinated patients; 45 (27.5%) patients were mutation negative. Nine patients (5.5%)
developed pneumonia. Eight patients (4.9%) had CT findings compatible with corona virus infection. Seven (4.3%) of the patients
received treatment in the intensive care unit, and 5 (3%) of the patients were intubated.
Conclusions: In conclusion, people who receive two doses of CoronaVac vaccine can be reinfected with mutant viruses, vaccine
significantly reduces the need for hospitalization, CT findings and intensive care.
Key words: SarsCov-2, CoronaVac vaccine, Sinovac, variant virus, Turkey

1. Introduction
SARS-CoV-2 (severe acute respiratory syndrome
coronavirus-2), which emerged in Wuhan, China in
December 2019, is responsible for the COVID-19
epidemic that currently affects the whole world [1,2]. As
of 30 June 2021, 181,344,227 cases have been detected all
over the world, and 3,934,252 confirmed deaths due to
COVID-19 have been reported globally1. SARS-CoV-2 is a
positive-sense, single-stranded RNA virus with a genome
of approximately 30 kb in length and reported to contain
14 open reading frames encoding 27 proteins [3]. Since
the beginning of the pandemic, SARS-Cov-2 genome
sequencing studies have enabled genomic epidemiology
studies of the origins, genetics and spread of viral variants
of the COVID-19 disease. As of May 2021, more than
1.2 million SARS-CoV-2 genome sequences have been

uploaded and shared through the GISAID (the Global
Initiative on Sharing Avian Influenza Data) database2
[4]. These sequencing studies and the realization of new
detections by monitoring variations in the SARS-CoV-2
genome ensured that genome changes have an observable
impact on virus biology and a number of variants (VOCs,
variant of concern) were quickly identified by late 2020 [4].
During the replication and spread of viruses, especially
RNA viruses such as SARS-CoV-2, changes (mutations)
develop in their genomes. The SARS-CoV-2 has a natural
RNA repair mechanism and therefore accumulates
mutations at a relatively slower rate than most other RNA
viruses. Regarding the rate of change in the virus, it has
been reported that it undergoes ∼1.1 × 10−3 changes
per site per year, corresponding to approximately one
change every 11 days [5]. In all virus genomes sequenced

1

WHO (2021) “WHO Coronavirus (Covid-19) Dashboard”, Available at: https://covid19.who.int/. [Accessed 30 June 2021].

2

GISAID (2021). Global initiative on sharing all influenza data; Available from: https://www.gisaid.org/. [Accessed 30 June 2021].
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to date, thousands of mutations have occurred since the
beginning of the pandemic, resulting in thousands of
new variants. Although many of the mutations do not
have a full effect, some mutations can add some new
characteristics to the virus, such as greater contagiousness
and easy spread. These situations can trigger the selection
of some variants and their becoming dominant after a
certain period. However, more recently, several variants
have been identified that appear to increase infectivity and
potentially have an impact on disease severity3. Several
more rapidly spreading variants of the SARS-CoV-2 have
recently been reported in the UK (Alpha, B.1.1.7), South
Africa (Beta, B.1.351), Brazil (Gamma, P.1), and India
(Delta, B.1.617), and determined in more 100 countries
[6], including Turkey. B.1.1.7 originated in the UK,
named as alpha variant, and was the first major SARSCoV-2 strain of VOCs that was both more contagious
and apparently more virulent [7]. The S protein (Spike)
protein N501Y mutation increases the binding affinity
of S protein and ACE2, while HV69-70del and Y144del
deletions in the N-terminal domain (NTD) also play a role
in ACE2 receptor binding or neutralizing antibody escape
[7,8]. In recent studies, it has been reported new mutation
situations that may result in the emergence of new and
even more infectious sublineages of B.1.1.7. [7]. Variant
viruses can trigger situations such as causing reinfection,
evasion of the immune response, affecting different age
groups, course of the disease, spreading and increasing
mortality rates. In addition to all these, it is thought that
it may reduce the effectiveness of the vaccine by avoiding
the immune response that occurs after vaccination [9,10].
A large number of potential vaccines against
COVID-19 have been developed at a rapid pace, and
as of December 2020, extensive mass vaccination
programs have been launched around the world [11].
As a result, it has been reported by the World Health
Organization (WHO) that a total of 2,660,756,547
doses of vaccine have been administered as of 27 June
2021, since the vaccination started1. As of January 13,
2021, Turkey granted an emergency use permit to the
inactivated virus-based ‘CoronaVac’ manufactured by
the Chinese biopharmaceutical company Sinovac [11,12].
Furthermore, WHO has approved the CoronaVac vaccine
for emergency use as of June 1, 20214. It was reported that
CoronaVac clinical trial in Brazil showed lower efficacy
numbers (50%) than in other countries such as Turkey

(83.5%) and Indonesia (65.3%)5.
In Turkey, data for researchers about COVID-19
positivity and vaccines are limited. Thus, the available
data from websites of the Ministry of Health were used.
Daily cases, deaths, vaccinated people numbers were
provided from the Ministry of Health. Healthcare workers
are at a higher risk of exposure to coronavirus than
other segments of society [13]. For this reason, health
workers were the first group to be vaccinated in Turkey. In
Turkey, COVID-19 vaccines started in mid-January, and
vaccination studies of healthcare workers and the group
over 65 years old were carried out quickly. Until the end
of April, only CoronaVac vaccine was available in Turkey
and the vaccination program was administered as two
doses of 3mcg 28 days apart. It can be assumed that this
situation provides us with maximum antibody formation
and protection due to the vaccine in March-April and early
May [14].
Data on the protection against variant viruses
of CoronaVac is quite limited. This study aims to
retrospectively evaluate the mutation status and clinical
picture in individuals who are positive for COVID-19
after at least two weeks of the second dose of CoronaVac
vaccine.
2. Materials and methods
2.1. Ethical considerations
Ethical permissions of this study were approved by both
the Republic of Turkey Ministry of Health COVID-19
Scientific Research Evaluation Commission and the
Pamukkale University Local Ethics Committee approval
date: 8/06/2021; number E-60116787-020-60569, (No: 11).
2.2. Sample selection and viral RNA isolation and RTqPCR
In this study, 164 cases who were diagnosed as COVID-19
positive at Pamukkale University Hospital between
21.03.2021 and 21.05.2021, although two doses of
CoronaVac vaccine were completed, were included. Cases
that completed at least 14 days or more after the second
dose were included in the study. 14 days after the second
dose of vaccine, these patients who were positive for
COVID-19 were regularly reported to our laboratory by
the Denizli Provincial Health Directorate for mutation
study. Among the test results of the same patient, only
one test result was included in the study. Vaccination data

FIND Because Diagnosis Matters (2021). SARS-CoV-2 variants Reports. Available from: https://www.finddx.org/wp-content/uploads/2021/03/covidvariants-report-FINAL-12MAR2021.pdf [Accessed 11 March 2021].
3

WHO (2021). WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations. Available at: https://www.
who.int/news/item/01-06-2021-who-validates-sinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations [Accessed
30 June 2021].
4

WHO report. Background document on the inactivated vaccine Sinovac-CoronaVac against Covid-19. Available at: WHO REFERENCE NUMBER:
WHO/2019-nCoV/vaccines/SAGE_recommendation/Sinovac-CoronaVac/background/2021.1. https://www.who.int/publications/i/item/WHO-2019nCoV-vaccines-AGE_recommendation-Sinovac-CoronaVac-background-2021.1 [Accessed 1 June 2021].
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of Pamukkale University Hospital health workers were
obtained from the Workplace Health and Safety Unit
within our hospital.
The diagnosis of COVID-19 for the samples sent to
our laboratory was determined by RT-PCR (Rotor Gene,
Qiagen, USA) using Bioseepdy SARS CoV-2 Double Gene
RT-qPCR Kit (Lot:2B01114NF25OG100-TK20, Turkey).
This kit can be used on nucleic acid extracts obtained from
nasopharyngeal aspirate/lavage, bronchoalveolar lavage,
nasopharyngeal swab, oropharyngeal swab, and sputum
samples with vNAT (viral nucleic acid buffer) extraction
buffer. Rapid diagnosis with the kit is performed by onestep reverse transcription (RT) and real-time PCR (RTqPCR) targeting the SARS-CoV-2 specific N and Orf1ab
gene region. The kit targets the human RNaseP gene for
sampling, nucleic acid extraction and inhibition control.
The kit allows the reaction result to be reached in less
than 50 min. Positive and negative patient results were
determined in accordance with the protocol determined
by the manufacturer. Subsequently, mutation analysis of
the positive patients after vaccination was performed.
2.3. Mutation detection by RT-qPCR
In our study, mutation detection of positive cases was
performed in RT-PCR (Rotor Gene, Qiagen, USA) device
using Biospeedy SARS-CoV-2 Variant Plus kit (Cat No:
BS-SY
WCOR-402-250/BS-SY-WCOR-402-500/BSSY-WCOR-402 1000, Turkey). The purpose of the kit is
to identify variants arising from strains such as B.1.1.7
(UK), B.1.351 (South Africa), P.1 (Brazil), B.1.525 (UK
and Denmark), B.1.526 (USA). “Bio-Speedy® SARSCoV-2 Variant Plus” kit, a one-step reverse transcription
and real-time PCR (RT-qPCR) test, is designed for the
qualitative detection of SARS-CoV-2 and variant strains
in nasopharyngeal swab, oropharyngeal swab, nasal swab,
nasopharyngeal aspirate, saliva and bronchoalveolar
lavage specimens. Detection of mutations was performed
on the basis of RT-PCR using the kit protocol specified by
the manufacturer.
2.4. Statistical analysis
The data were analysed with the SPSS package program
(IBM SPSS Statistics 25). Continuous variables are given
as mean ± standard deviation and categorical variables as
numbers and percentages.
3. Results
Between 28.03.2021 and 17.05.2021, 13,316 PCR test
results were approved in Pamukkale University hospital.
Of these, 1888 patient test results were detected as positive
and 11,428 as negative. Among 1888 PCR-positive patients,
164 (8.7%) were double-dose vaccinated and 1724 (91.3%)
unvaccinated. The vaccination rate among the COVID-19
PCR-positive patients was very low. Mutation analysis was
performed in 434 of 1888 patients who were positive for

COVID-19, and UK mutations were commonly detected.
Of the studied patients, 296 (68.2%) were found as UK
(Alpha, B.1.1.7), 6 (1.3%) South Africa (Beta, B.1.351),
Brazil (Gamma, P.1), 132 (30.5%) mutation negative.
Among 434 patients whose mutations were studied, 164
were patients who were positive at least 15 days after the
double dose vaccination. Of 164 patients, 116 (70.7%)
were found UK (Alpha, B.1.1.7) mutation, 45 (27.5%)
were found mutation negative, 3 (1.8%) were found South
Africa (Beta, B.1.351), Brazil (Gamma, P.1) mutations
(Figure).
The mean age of 164 patients in the study was 57.7
years. Patients’ PCR tests were positive on average 51.8
days after the second dose of vaccine. Fifty-one patients
(31.1%) were healthcare workers. Fifty-nine were males
(36%) and 105 were females (64%). While no symptoms
developed in 60 patients (36.6%), at least one symptom
developed in 104 patients (63.4%). Nine patients (5.5%)
developed pneumonia. Eight patients (4.9%) had CT
findings compatible with coronavirus infection. Seven
patients (4.3%) received treatment in the intensive care
unit. Five patients (3%) were intubated. Four patients
(2.4%) died. Of the 4 patients who died, 2 were UK
mutations and 2 were nonmutant variants. These clinical
data are given in Table.
4. Discussion
SARS-CoV-2 is a novel coronavirus that has infected
more than 181 million people and caused approximately
4 million deaths as of the end of June 2021 worldwide1.
Molecular genetic studies on the SARS-COV2 virus, such as
genomic surveillance, differentiations, mutation detection,
variant analysis, are of critical importance, especially in
terms of diagnosis, treatment, and vaccination [15,16].
Further experimental research is needed to determine
what changes the variants exhibit to evade immunity,
the effect on sequence data and viral phenotypes. Studies
are ongoing to assess whether VOCs reduce the efficacy
and effectiveness of approved vaccines. Scientists use
laboratory experiments and clinical data to assess whether
individual mutations have an effect on vaccine efficacy3.
Safety, tolerability, and immunogenicity of CoronaVac
vaccine in individuals aged 18–59 years have been reported
with the data of randomized, double-blind, and placebocontrolled phase 1 and phase 2 trials [17]. As a result of the
study, CoronaVac vaccine was shown to be well-tolerated
and induced humoral response against SARS-COV-2, thus
providing support for immediate use approval in Chine
and phase 3 studies in clinical trials that are ongoing in
Brazil (NCT04456595), Indonesia (NCT04508075), and
Turkey (NCT04582344)5. According to results from phase
3 studies, CoronaVac vaccine efficacy against COVID-19
was found as 83.5% in Turkey5 [18] and 65.3% in Indonesia
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Variant Distrubution
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Figure. 164 people were included in the study and COVID-19 diagnosis and mutation analyses were determined by RTPCR. 116 (70.7%) were UK (Alpha, B.1.1.7) mutation, 45 (27.5%) were mutation negative, 3 (1.8%) were South Africa
(Beta, B.1.351), Brazil (Gamma, P.1) mutations determined in 164 double doses CoronaVac vaccinated people.
Table. Clinical data status in 164 subjects who received two doses of CoronaVac vaccine and were
reinfected with SARS-Cov-2 virus 15 days after the second dose CoronaVac vaccinated people.
Symptom

Pneumonia

CT finding

Need for
intensive care

Need for
intubation

Ex

Yes

104 (63.4%)

9 (5.5%)

8 (4.9%)

7 (4.3%)

5 (3%)

4 (2.4%)

No

60 (36.6%)

155 (94.5%)

156 (95.1%)

157 (95.7%)

159 (97%)

159 (97%)

[19]. In Brazil, this efficacy rate was found to be 50.7%5.
However, the efficacy rate of mRNA-based vaccines such
as Pfizer/BioNTech and Moderna was found to be higher
and reported as 95% [20] and 94.5% [21], respectively [22].
CoronaVac is a Vero cell-based, aluminium hydroxideadjuvanted,
β-propiolactone-inactivated
vaccine
dependent on the CZ02 strain of SARS-CoV-2 which was
isolated from the bronchoalveolar lavage of a hospitalized
patient and is firmly identified with the 2019-nCoVBetaCoV Wuhan/WIV04/2019 strain5 [12]. Over time,
mutations have triggered the original Wuhan virus to
be replaced by a vastly different number of variants of
concern viruses. Scientists are curiously working on
how this will affect the effectiveness of existing vaccines.
Nonetheless, various variations have raised worry because
of transformations amassing especially in the S-quality
and causing changes in the immunodominant epitopes
of the trimeric spike protein. The D614G and B.1.1.7
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variants of the SARS-COV-2 virus were neutralized by
the vaccinees’ sera, demonstrating that these changes will
probably not weaken the neutralizing antibody capacity
induced by vaccination or natural infection. In any case, it
ought to be noticed that the neutralizing titre of these sera
was five-fold lower against the B.1.351 variation, which
means that the amino acid changes accumulating in this
variation are potentiating the escape of the infection from
the humoral immunity. Nevertheless, more than 92% of
vaccines demonstrated measurable neutralizing antibody
titers against variant B.1.351. [23].
It is not currently known exactly how high neutralizing
antibody titers are required against a particular virus
variant for antibody-mediated protection against SARSCov-2 [23]. Although the exact efficacy of the CoronaVac
vaccine against mutant viruses is not reported, it is thought
that this vaccine reduces the course of hospitalization
and severe illness. It is reported that the effectiveness of

ÇALIŞKAN et al. / Turk J Med Sci
CoronaVac 14 days after the second dose in Chile was
determined as 67% (65%–69%) effectiveness to prevent
symptomatic COVID-19, 85% (83%–87%) effectiveness to
prevent hospital admission, 89% (84%–92%) effectiveness
to prevent intensive care unit (ICU) admission, and 80%
(73%–86%) effectiveness to prevent death [24]. No study
has yet been presented to evaluate the impact of the
CoronaVac vaccine on the population level [14].
Although the publication of information about the
protective effect of the Sinovac vaccine in Turkey is still
limited, the first report on the effectiveness of the Sinovac
vaccine on healthcare workers has been published recently
[14]. Akpolat and Uzun (2021) have reported that the
ratio of the death of healthcare workers to all residents
decreased after vaccination. They have detected that
vaccination indicates about 90% protection from death
[14]. In our study, the number of patients who were
positive for COVID-19 PCR in the specified date range
was 1888. Mutation analyses of these 434 patients were
completed and UK mutations were commonly detected.
Mutation distributions were found to be 296 (68.2%) UK
mutation, 6 (1.3%) South Africa-Brazil mutation, 132
(30.5%) mutation negative. Among those with positive
PCR test, 164 were vaccinated with double dose CoronaVac
vaccine and COVID-19 PCR tests were positive 15 days
after the second dose. It was determined that 164 of 434
patients whose mutations were studied were positive 15
days after the double dose vaccine and these patients were
included in the study. It was determined that 116 (70.7%)
of the people who were infected after vaccinations had the
UK mutation, 45 (27.5%) were mutation negative, and
3 (1.8%) had a South African-Brazil mutation. Among
these 164 people, 51 were healthcare workers. Of these
164 people whose PCR tests were positive on average
51.8 days after the second dose of vaccine, 60 (36.6%)
did not develop symptoms, while 104 (63.4%) developed
at least one symptom. In addition, according to the data
obtained, 9 (5.5%) of the patients developed pneumonia,
while pneumonia did not develop in the vast majority
(155 people, 94.5%). While 8 (4.9%) of the patients had
CT findings compatible with coronavirus infection, no CT
findings were observed in 156 (95.1%) patients. While 7
(4.3%) of the patients received treatment in the intensive
care unit, 157 (95.7%) did not need intensive care. While
5 (3%) of the patients were intubated, 159 (97%) were not
intubated. Of the 164 people included in the study, 4 died
in our study group. The average age of those who are ex is
quite advanced and determined as 82.2 ages in our study.
Similar data were obtained in another study. At least one

risk factor has been identified in all vaccinated deaths.
Those who were vaccinated and died were determined
to be older, and approximately 28% of those who died
in the prevaccination period were younger than 55 years
old, while the youngest of those who died after being
vaccinated was 56 years old [14]. According to our results,
while the rate of 1724 patients who were unvaccinated and
whose COVID-19 test was positive among the applications
made to Pamukkale University Hospital was determined
as 12.9%, this rate was found to be 1.2% in double-dose
vaccinated individuals. In this context, it was determined
within the scope of this study that the Coronavac vaccine
caused a serious decrease in the rate of positivity in the
COVID-19 PCR test. All these results show us that, as
a result of variant analyses in individuals who received
two doses of CoronaVac vaccine and were infected
with COVID-19, they can be reinfected with mutant
viruses, but the vaccine significantly reduces the need for
hospitalization, CT findings and intensive care. In another
study in Turkey with CoronaVac, Akpolat and Uzun (2021)
have reported that despite vaccination, healthcare workers
continued to have COVID-19 infection, but less than
the prevaccination period. They found that CoronaVac
vaccine also reduced deaths by 95% [14].
5. Conclusion
In conclusion, the first data in Turkey regarding the
mutation distributions in individuals who had received two
doses of CoronaVac vaccine were shared within the scope
of our study. In this study, it was observed that the need for
hospitalization and intensive care for individuals who were
vaccinated with CoronaVac vaccine decreased, but it was
observed that reinfection with mutant viruses continued.
Depending on the variety of variants that change day by
day, planning detailed studies and determination of vaccine
efficacy are important in terms of the up-to-dateness of
vaccination studies. It is recommended to conduct more
comprehensive studies with a larger population.
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